ArticlePediatric cardiology2026
Single-Center Experience with Sacubitril/Valsartan in Patients with Congenital Heart Disease.
Article in Pediatric cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Pharmacokinetics in the Fontan circulation: a multi-organ puzzle.European heart journal. Cardiovascular pharmacotherapy · 2026Review
- Current concepts and challenges in pediatric diastolic dysfunction and heart failure with preserved ejection fraction.Pediatric research · 2026Review
- Challenges in managing pediatric heart failure, especially in resource-limited settings.Annals of pediatric cardiologyArticle
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure is a significant cause of morbidity and mortality in patients with congenital heart disease (CHD). While clinical guidelines for acquired cardiovascular diseases exist, evidence-based therapies for heart failure in CHD are lacking. Angiotensin II receptor blocker and neprilysin inhibitor (ARNI) therapy has shown efficacy in adults with heart failure, reducing cardiovascular mortality and hospitalizations, but its use in pediatric CHD patients remains underexplored. This study aimed to evaluate the safety and efficacy of Sacubitril/Valsartan (ARNI) in pediatric and young adult patients with CHD. We conducted a retrospective chart review of 29 patients who received ARNI therapy between August 2021 and December 2023. The patients' age ranged from 5.3 months to 22.8 years. Fifteen of the 29 patients (52%) had single ventricle CHD. The median time for follow-up since ARNI initiation was 8 months (range 6 days-2.4 years). Twelve (41%) patients experienced hypotension which necessitated dose adjustments, temporary withholding of the medication, or discontinuation. Additionally, 2 patients developed acute kidney injury. The medication had to be discontinued in 7 patients (24%) due to hypotension (3 or 10%), AKI (2 or 7%) and progression of heart failure needing advanced cardiac therapies (2 or 7%). A comparative analysis of clinical and laboratory data before and after ARNI therapy revealed a significant reduction in systolic blood pressure (p = 0.01), as well as increases in serum creatinine and potassium levels (p = 0.02 and p = 0.03, respectively). Additionally, there was a trend toward improvement in ventricular systolic function observed on echocardiogram after ARNI therapy; however, this was in the context of patients receiving concomitant other oral heart failure medications. Our findings highlight the need for careful monitoring and individualized management of ARNI therapy in pediatric CHD patients. Larger, well-designed trials are essential to establish clear treatment guidelines and optimize the use of ARNI therapy in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.